 Asian Scientist Magazine |
X-BODY, Jiangsu Hengrui To Develop Novel Therapeutic Antibodies
Asian Scientist Magazine AsianScientist (Apr. 15, 2013) – X-BODY Biosciences has signed an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd., in which Hengrui will develop and commercialize novel therapeutic antibodies for age-related macular degeneration (AMD) in … |
Competitor Analysis: Antibody-Drug Conjugates (ADC)PipelineReview.com (press release)The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting an…
|
NIH researchers’ clinical trials show promising results in treating lymphoma …
pharmabiz.com Wyndham Wilson, head of NCI’s Lymphoma Therapeutics Section, and colleagues conducted the trial, in which every patient received the drugs etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab in a regimen known as … |
|
New Report Analyzes the Potential of Therapeutic Monoclonal Antibodies in India
PR.com (press release) Globally there are only 2 approved biosimilar monoclonal antibodies with Reditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian generic manufacturer) being one of them. As a result, India and its biosimilar manufacturers can be … Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market …SBWire (press release) |
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market …SBWire (press release)The leading business intelligence provider, has released its latest research, Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market Character…
SKNVibes.comNew Promise for an HIV Vaccine as Researchers Overcome Crucial ObstacleSKNVibes.comApril 12th, 2013 — In a crucial step towards developing a successful HIV vaccine, researchers have been able, for the first time, to stimulate immune cells …
 ThinkProgress |
April 12 News: McKibben Says The Planet’s Fever Is Spiking, But Antibodies Are …
ThinkProgress as the planet runs its spiking fever, the antibodies are starting to kick in. We know what the future holds unless we resist. And so resist we will. If Gina McCarthy gets confirmed to be the next EPA Administrator, she will have a “common-sense … |
|
MS: Schubhalbierung durch Daclizumab HYP?
DocCheck News “Innerhalb eines Jahres reduzierte Daclizumab HYP die Häufigkeit erneuter Erkrankungsepisoden bei Patienten mit einer schubförmig remittierenden Multiplen Sklerose um 54 Prozent”, berichtet Professor Ralf Gold, Direktor der Neurologischen Klinik am St. |
 Counsel & Heal |
Adding rituximab helps treat mediastinal B-cell lymphoma
Curetoday.com (press release) NEW YORK (Reuters Health) – A phase II trial in patients with primary mediastinal B-cell lymphoma has found that rituximab can improve the effectiveness of a six-drug anti-cancer cocktail, nearly eliminating the need for radiotherapy. The five-year … NIH trial shows promising results in treating a lymphoma in young peopleNational Institutes of Health (press release) Chemotherapy, no radiation for lymphoma type effectiveUPI.com New Treatment For Lymphoma May Mean Skipping RadiationCounsel & Heal |
Counsel & Heal |
Chemotherapy, no radiation for lymphoma type effective
UPI.com Dr. Wyndham Wilson of the National Cancer Institute, part of the National Institutes of Health, and colleagues conducted the trial, in which every patient received the drugs etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab. New Treatment For Lymphoma May Mean Skipping RadiationCounsel & Heal |